HSCS - HeartSciences Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

HSCS

HEARTSCIENCES INC.

NASDAQ

$3.03

▼ DOWN 2.88% (-0.09)

KEY STATISTICS

Market Cap$6.54 M

52w High$3.80

52w Low$1.63

Dividend Yield—

Frequency—

P/E-0.77

Volume45.46K

Shares Out.2.16M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Andrew Simpson

COMPENSATION 2026

Salary$345,833

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$527,174

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 16, 2022

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$3.00

Target Low$3.00

Target Median$3.00

Target Consensus$3.00

UPCOMING EARNINGS

DateSep 10, 2026

DayThursday

Rev. Est.$100.00K

SEP

THU

SPLIT RECORD

DATE	TYPE	RATIO
2024-05-17	Reverse	1:100

PRICE

$3.03 ▼ DOWN 2.88% (−$0.09)

OVERLAYS

About HeartSciences Inc.

https://heartsciences.com ↗

HeartSciences Inc. develops AI-enhanced ECG solutions, including the MyoVista wavECG device and cloud platform, to improve detection of cardiac dysfunction and expand ECG clinical utility.

INDUSTRY

Medical - Devices

A PRODUCT HEARTSCIENCES INC. IS KNOWN FOR

MyoVista® wavECG™ Device

The MyoVista® wavECG™ is HeartSciences' AI-enabled 12-lead ECG device that provides traditional cardiac data and advanced diagnostic insights typically requiring imaging, with a pending FDA 510(k) clearance.